Immunological evaluation of OMV(PagL)+Bap(1-487aa) and AbOmpA(8-346aa)+Bap(1-487aa) as vaccine candidates against Acinetobacter baumannii sepsis infection.
Acinetobacter baumannii is an important nosocomial pathogen that causes a high morbidity and mortality rate in infected patients with sepsis form. The surface exposed virulence proteins and serum resistance factors helping to dissemination of this bacterium to bloodstream are the most promising vaccine candidates against this microorganism. In this project we immunologically evaluated OMV(PagL)+Bap(1-487aa) and AbOmpA (8-346aa)+Bap(1-487aa) as combination forms as well as Bap(1-487aa), AbOmpA(8-346aa) and OMV(PagL) singly, with addition of alum adjuvant as vaccine candidates. The titers of total IgG, IgG1 and IgG2c as well as concentration of IL-4 and IFN-γ and survival rates were measured in a C57BL/6 murine model with disseminated sepsis. The ratio of IgG1/IgG2c and profile of IL-4/IFN-γ in OMV (PagL)+Bap (1-487aa) formulation shows the humoral and cellular immune responses have been induced robustly and have created a full protection against A. baumannii ATCC 19606 and MDR AB-44 strains. We found that the two combination vaccine candidates were protective and induced both Th1 and Th2 responses.
Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.
Farzad
F
Badmasti
Department of Immunology, Pasteur Institute of Iran, Tehran,Iran.
Soheila
S
Ajdary
Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran.
Saeid
S
Bouzari
Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Abbas Ali Imani
AA
Fooladi
Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran. Electronic address: shahcheragifereshteh@yahoo.com.
Fereshteh
F
Shahcheraghi
Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran. Electronic address: d.siadat@gmail.com.
Seyed Davar
SD
Siadat
D000151:Acinetobacter Infections / Q000276:immunology* / Q000382:microbiology; D040981:Acinetobacter baumannii / Q000276:immunology*; D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D058491:Bacterial Load / Q000276:immunology; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology; D005260:Female; D007114:Immunization; D007074:Immunoglobulin G / Q000276:immunology; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D053208:Kaplan-Meier Estimate; D008810:Mice, Inbred C57BL; D018805:Sepsis / Q000276:immunology* / Q000382:microbiology*; D013154:Spleen / Q000382:microbiology / Q000473:pathology
D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D015847:Interleukin-4; D007371:Interferon-gamma
Acinetobacter baumannii vaccine candidates; Biofilm-associated protein (Bap); Outer membrane protein of A. baumannii (AbOmpA); Outer membrane vesicle (OMV)